RT Journal Article
SR Electronic
T1 Biological Therapy for Psoriatic Arthritis in Clinical Practice: Outcomes Up to 2 Years
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 2362
OP 2368
DO 10.3899/jrheum.091477
VO 37
IS 11
A1 LIISA M. VIRKKI
A1 BINDU C. SUMATHIKUTTY
A1 MERJA AARNIO
A1 HEIKKI VALLEALA
A1 RIITTA HEIKKILÄ
A1 MARKKU KAUPPI
A1 KRISTA KARSTILA
A1 LAURA PIRILÄ
A1 PÄIVI EKMAN
A1 SIRPA SALOMAA
A1 MATTI ROMU
A1 JOUKO SEPPÄLÄ
A1 HELENA NIINISALO
A1 YRJÖ T. KONTTINEN
A1 DAN C. NORDSTRÖM
YR 2010
UL http://www.jrheum.org/content/37/11/2362.abstract
AB Objective. To evaluate the performance of biological drugs in psoriatic arthritis (PsA) in a routine care setting, using the Finnish national register of biological treatment (ROB-FIN). Methods. Patients with PsA who started therapy with infliximab or etanercept between June 2000 and February 2006 (n = 127) were followed for up to 24 months. Response was evaluated using American College of Rheumatology response criteria including individual measures. Results. Significantly diminished values for swollen and tender joints, patient’s global and pain assessments, doctor’s global assessment of disease activity, erythrocyte sedimentation rate, C-reactive protein, and Health Assessment Questionnaire score were observed within 3 months after commencement of both infliximab and etanercept. Values remained significantly lower throughout the 24 months of followup. ACR20 response at 3 months was 79% (n = 22/28) for infliximab and 76% (n = 34/45) for etanercept. The first biological drug was discontinued in 16% due to lack of effectiveness and in 6% due to adverse events. Conclusion. Anti-tumor necrosis factor-α therapy, often combined with conventional disease-modifying antirheumatic drugs, appeared to have limited toxicity and persistent effectiveness for up to 2 years in a cohort of Finnish patients with severe peripheral PsA.